臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :2856708
	造訪人次 : 53592586 線上人數 : 806 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"sequist l v"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 6-15 / 40 (共4頁)
1 2 3 4 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-04-23T05:56:29Z	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study	Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W.
臺大學術典藏	2021-04-23T05:56:26Z	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC	Awad M.M.;Gadgeel S.M.;Borghaei H.;Patnaik A.;Chih-Hsin Yang;Powell S.F.;Gentzler R.D.;Martins R.G.;Stevenson J.P.;Altan M.;Jalal S.I.;Panwalkar A.;Gubens M.;Sequist L.V.;Saraf S.;Zhao B.;Piperdi B.;Langer C.J.; Awad M.M.; Gadgeel S.M.; Borghaei H.; Patnaik A.; CHIH-HSIN YANG; Powell S.F.; Gentzler R.D.; Martins R.G.; Stevenson J.P.; Altan M.; Jalal S.I.; Panwalkar A.; Gubens M.; Sequist L.V.; Saraf S.; Zhao B.; Piperdi B.; Langer C.J.
臺大學術典藏	2020-12-02T02:34:00Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A.
臺大學術典藏	2020-08-13T06:33:49Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.
臺大學術典藏	2020-05-26T09:27:08Z	Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma	Pao W.; Riely G; Ladanyi M; Zakowski M.F; Taron M; Rosell R; Pao W.;Riely G;Ladanyi M;Zakowski M.F;Taron M;Rosell R;Waltman B;Ji H;Chih-Hsin Yang;Chen H;Sequist L.V;Jackman D.M;Sima C.S;Girard N; Girard N; Sima C.S; Jackman D.M; Sequist L.V; Chen H; CHIH-HSIN YANG; Ji H; Waltman B
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A.
臺大學術典藏	2020-05-26T09:27:06Z	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1	Chmielecki J; Lin Y.-L; Pan Y; Wang L; De Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; CHIH-HSIN YANG; Miller V.A; Riely G.J; Kris M.G; Engelman J.A; Vnencak-Jones C.L; Dias-Santagata D; Ladanyi M; Pao W.; Pao W.;Ladanyi M;Dias-Santagata D;Vnencak-Jones C.L;Engelman J.A;Kris M.G;Riely G.J;Miller V.A;Chih-Hsin Yang;Fidias P;Fernandez-Cuesta L;Kiura K;Toyooka S;Aoe K;Shien K;De Stanchina E;Wang L;Pan Y;Lin Y.-L;Chmielecki J;Moran T;Arcila M.E;Sequist L.V;Ohashi K; Ohashi K; Sequist L.V; Moran T; Arcila M.E
臺大學術典藏	2020-05-26T09:27:01Z	Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations	Chih-Hsin Yang;Hirsh V;Schuler M;Yamamoto N;O'Byrne K.J;Mok T.S.K;Zazulina V;Shahidi M;Lungershausen J;Massey D;Palmer M;Sequist L.V.; CHIH-HSIN YANG; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V.
臺大學術典藏	2020-05-26T09:27:01Z	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations	Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M.
臺大學術典藏	2020-05-26T09:26:58Z	Reply to E.R. Haspinger et al	Chih-Hsin Yang;Sequist L.V.; CHIH-HSIN YANG; Sequist L.V.

顯示項目 6-15 / 40 (共4頁)
1 2 3 4 > >>
每頁顯示[10|25|50]項目